An interventional study of QT Scanner: Quantitative Transmission Ultrasound Breast Imaging System and ABUS: Invenia™ ABUS, Invenia Automated Breast Ultrasound System, ABUS, GE ABUS in Breast Cancer, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Stanford University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Breast Neoplasms by Stanford University — 6 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Stanford University.
Among the 65 studies in Breast Neoplasms by Stanford University, this one is the 22nd largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2027, is one of 24 with no phase, and was the 65th registered.
14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →6 of the 65 studies in Breast Neoplasms by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+ · Women only
Stanford University · Sites in United States
Ages 21+ · Women only · Healthy volunteers
Stanford University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 5
First in 1993; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 40 across the 46 interventional studies, 100 across the 17 observational. Of the 51 that completed or were terminated, 17 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,172 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
2 of the studies in Breast Neoplasms by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT01035112Stanford UniversityMagnetic Resonance Imaging of Breast Cancer | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 65 studies in Breast Neoplasms by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study addresses an unmet need to improve the diagnostic accuracy of: 1. supplemental breast cancer screening with whole breast US and 2. the evaluation of disease extent in women with newly diagnosed breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant will undergo one (1) imaging examination using the investigational QT Scanner and one (1) imaging examination using the FDA-cleared Invenia™ Automated Breast Ultrasound System (ABUS).
Device: QT Scanner: Quantitative Transmission Ultrasound Breast Imaging System · Device: ABUS: Invenia™ ABUS, Invenia Automated Breast Ultrasound System, ABUS, GE ABUS
QT: The scanner is an FDA-cleared imaging technology that uses transmission ultrasound to generate quantitative maps of breast tissue properties (e.g., speed of sound, absorption) as well as provides reflection ultrasound images. It is a non-invasive, non-ionizing imaging modality and does not involve administration of a drug or biologic. Each participant will undergo one (1) imaging examination using the QT Scanner for comparison with images obtained using automated breast ultrasound (ABUS)
ABUS is FDA-approved for both supplemental breast cancer screening in women with radiographically dense breast tissue, and for diagnostic breast ultrasound imaging. Each participant will undergo one ABUS imaging examination for comparison with images obtained using the investigational QT Scanner.
Number of Additional Breast Cancer Lesions Detected
The number of additional contralateral and ipsilateral breast cancer lesions detected using the QT scanner and ABUS as reported by study radiologists in women with dense breast tissue and newly diagnosed unilateral breast cancer.
Time frame: Baseline
BI-RADS Assessment
Radiologists' diagnostic assessment of contralateral and ipsilateral breast cancer lesions identified using the QT Scanner and ABUS, as measured using the Breast Imaging Reporting and Data System (BI-RADS) classification categories.
Time frame: Baseline
Numerical Likelihood of Malignancy
Radiologists will assess the likelihood of malignancy for contralateral and ipsilateral breast cancer lesions detected by QT Scanner and ABUS. Diagnostic confidence will be measured using the numerical likelihood-of-malignancy estimates assigned to identified lesions.
Time frame: Baseline
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Of 2,668 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.
Counting every sponsor, half of 2,778 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.